Coherus Oncology, Inc.
CHRS
$1.22
$0.065.17%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -24.15% | -56.32% | -65.62% | -71.70% | -47.80% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -24.15% | -56.32% | -65.62% | -71.70% | -47.80% |
| Cost of Revenue | -51.82% | -64.62% | -71.41% | -74.95% | 2.16% |
| Gross Profit | 103.41% | -39.13% | -55.67% | -66.45% | -83.96% |
| SG&A Expenses | -17.59% | -23.66% | -30.79% | -34.82% | -30.05% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.48% | -31.75% | -40.35% | -43.84% | -18.79% |
| Operating Income | 18.53% | 8.60% | 9.25% | 6.41% | -15.31% |
| Income Before Tax | 25.05% | 21.44% | 13.03% | 7.17% | -15.01% |
| Income Tax Expenses | -- | -- | -- | -- | 100.00% |
| Earnings from Continuing Operations | 25.05% | 21.32% | 12.88% | 7.02% | -15.21% |
| Earnings from Discontinued Operations | 37.15% | 73.98% | -59.27% | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 34,538.00% | 712.65% | -120.85% | 111.98% | 99.79% |
| EBIT | 18.53% | 8.60% | 9.25% | 6.41% | -15.31% |
| EBITDA | 18.40% | 8.81% | 9.74% | 7.34% | -14.77% |
| EPS Basic | 17,176.92% | 582.47% | -62.18% | 110.42% | 99.70% |
| Normalized Basic EPS | -57.10% | -62.07% | -51.37% | -30.72% | 22.99% |
| EPS Diluted | 10,197.67% | 559.65% | -64.15% | 109.22% | 99.51% |
| Normalized Diluted EPS | -57.10% | -62.07% | -51.37% | -30.72% | 22.99% |
| Average Basic Shares Outstanding | 2.05% | 5.90% | 12.72% | 21.94% | 32.74% |
| Average Diluted Shares Outstanding | 2.05% | 5.90% | 12.72% | 21.94% | 32.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |